Wire
UBS Adjusts Price Target on Beta Bionics to $22 From $24, Maintains Buy Rating
Beta Bionics (BBNX) has an average rating of overweight and mean price target of $20, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $15.98, Change: $-0.01, Percent Change: -0.06%
$BBNX
